Compare Sunrun Inc (RUN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sunrun Inc vs TG Therapeutics Inc — how do they compare? Sunrun Inc trades at $9.8 (market cap $2.42B), while TG Therapeutics Inc trades at $49.54 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 3.2× Sunrun Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals.
| RUN | TGTX | |
|---|---|---|
Market Cap | $2.42B | $7.64B |
Sector | Technology | Health |
52-Week High | $21.41 | $59.06 |
52-Week Low | $9.38 | $26.94 |
Enterprise Value | $16.93B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sunrun (RUN) trades at $9.79, down 0.81% amid bearish technical signals despite strong earnings beats. The company shows solid profitability with 11.59% net margin and attractive valuation metrics including P/E of 6.82 and P/B of 0.69. Recent Q2 2026 results beat expectations with $0.42 EPS versus $0.23 estimate, though shares declined on reduced full-year guidance and Goldman Sachs price target cut from $18 to $15.
While fundamentals remain strong with growing storage adoption and positive cash generation, near-term headwinds include guidance reductions and solar sector volatility. Analyst consensus remains bullish with $14.38 price target representing 47% upside potential, but investors face execution risks amid the company's shift toward direct sales and competitive market pressures.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
